Carmustine (BCNU) is an FDA-approved anti-cancer drug for the treatment of certain types of brain tumors including glioblastoma. Unfortunately, to reach the necessary therapeutic levels in the brain, BCNU needs to be administrated intravenously at a high dosage to compensate for its accumulation in various nonspecific organs, leading to severe adverse side effects, such as bone marrow suppression, pulmonary fibrosis, and hepatic toxicity.
